Brief: Fusion Pharmaceuticals Provides Updates On FPI-1434 And FPI-1966 Clinical Programs
09/06/2022 12:34
June 9 (Reuters) - Fusion Pharmaceuticals Inc FUSN.O :
* FUSION PHARMACEUTICALS- IN FPI-1434 TRIAL, EXPECTS TO
REPORT
PHASE 1 SAFETY, PHARMACOKINETICS, IMAGING DATA, DETAILS ON
DOSING REGIMEN, IN H1 2023
* FUSION PHARMACEUTICALS PROVIDES UPDATES ON FPI-1434 AND
FPI-1966
CLINICAL PROGRAMS
* FUSION PHARMACEUTICALS INC- ALSO UPDATING GUIDANCE FOR
FPI-1966
AND EXPECTS TO DOSE FIRST PATIENT IN THIS STUDY IN SECOND HALF
OF 2022
Source text for Eikon: ID:
Further company coverage: FUSN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fusion Pharmaceuticals
See all newsBrief: Acquisition Of Fusion Pharmaceuticals Completed
Brief: Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement
Brief: Fusion Pharmaceuticals Shareholders Approve Acquisition By Astrazeneca
Brief: Fusion Pharmaceuticals Shareholders Approve Acquisition By Astrazeneca
Fusion Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary